Abivax SA (AAVXF)
15.15
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 953.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -5.31% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 4.399 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 86.53% |
Profile
| Abivax SA is a France based biotechnology company. It is focused on using antiviral technology platform targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein's in the nucleus or the cytoplasm of the infected cell during viral infection, Immune stimulation platform focuses on invariant natural killer agonists and Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma. |
| URL | https://www.abivax.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Abivax SA is a France based biotechnology company. It is focused on using antiviral technology platform targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein's in the nucleus or the cytoplasm of the infected cell during viral infection, Immune stimulation platform focuses on invariant natural killer agonists and Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma. |
| URL | https://www.abivax.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | Apr. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |